Illumina, and Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, has announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus’s comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients.
“In the era of true precision medicine, every patient who is battling complex disease should be routed to the optimal therapy based on molecular insights,” said Everett Cunningham, Chief Commercial Officer of Illumina. “We envision a world where the full range of molecular profiling is available as part of the standard of care—not just in cancer, but in cardiology, neurology, immunology and every other category of disease.”
